ATAI
6:45 AM
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley's lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly's neuroscience pipeline to address some of the most challenging conditions in mental health INDIANAPOLIS and NEW YORK, July 16, 2026 /PRNewswire/ -- Eli
ataibeckley.com